Inhibitors of serine proteases as potential therapeutic agents: The road from thrombin to tryptase to cathepsin G

被引：43

作者：

Maryanoff, BE ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Spring House, PA 19477 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 04期

关键词：

D O I：

10.1021/jm030493t

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：769 / 787

页数：19

共 164 条

[1] Diheteroarylmethanes .5. E-Z isomerism of carbanions substituted by 1,3-azoles: C-13 and N-15 pi-charge shift relationships as source for mapping charge and ranking the electron-withdrawing power of heterocycles [J].

Abbotto, A ;

Bradamante, S ;

Pagani, GA .

JOURNAL OF ORGANIC CHEMISTRY, 1996, 61 (05) :1761-1769

[2] Unique overlap in the prerequisites for thrombin inhibition and oral Bioavailability resulting in potent oral antithrombotics [J].

Adang, AEP ;

de Man, APA ;

Vogel, GMT ;

Grootenhuis, PDJ ;

Smit, MJ ;

Peters, CAM ;

Visser, A ;

Rewinkel, JBM ;

van Dinther, T ;

Lucas, H ;

Kelder, J ;

van Aelst, S ;

Meuleman, DG ;

van Boeckel, CAA .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (20) :4419-4432

[3] Nonpeptidic chymase inhibitors: Design and structure-activity relationships of pyrimidinone derivatives based on the predicted binding mode of a peptidic inhibitor [J].

Akahoshi, F .

CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (15) :1191-1199

[4] Chymase inhibitors and their therapeutic potential [J].

Akahoshi, F .

DRUGS OF THE FUTURE, 2002, 27 (08) :765-770

[5] Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic α-keto heterocycles as novel inhibitors of human chymase [J].

Akahoshi, F ;

Ashimori, A ;

Sakashita, H ;

Yoshimura, T ;

Imada, T ;

Nakajima, M ;

Mitsutomi, N ;

Kuwahara, S ;

Ohtsuka, T ;

Fukaya, C ;

Miyazaki, M ;

Nakamura, N .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (08) :1286-1296

[6] Peptidyl alpha-keto thiazole as potent thrombin inhibitors [J].

Akiyama, Y ;

Tsutsumi, S ;

Hatsushiba, E ;

Ohuchi, S ;

Okonogi, T .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (05) :533-538

[7] Non-peptidic chymase inhibitors [J].

Aoyama, Y .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (09) :1423-1428

[8] DESIGN OF ENZYME-INHIBITORS USING ITERATIVE PROTEIN CRYSTALLOGRAPHIC ANALYSIS [J].

APPELT, K ;

BACQUET, RJ ;

BARTLETT, CA ;

BOOTH, CLJ ;

FREER, ST ;

FUHRY, MAM ;

GEHRING, MR ;

HERRMANN, SM ;

HOWLAND, EF ;

JANSON, CA ;

JONES, TR ;

KAN, CC ;

KATHARDEKAR, V ;

LEWIS, KK ;

MARZONI, GP ;

MATTHEWS, DA ;

MOHR, C ;

MOOMAW, EW ;

MORSE, CA ;

OATLEY, SJ ;

OGDEN, RC ;

REDDY, MR ;

REICH, SH ;

SCHOETTLIN, WS ;

SMITH, WW ;

VARNEY, MD ;

VILLAFRANCA, JE ;

WARD, RW ;

WEBBER, S ;

WEBBER, SE ;

WELSH, KM ;

WHITE, J .

JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) :1925-1934

[9] Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: Transition state inhibitors [J].

Bachand, B ;

Tarazi, M ;

St-Denis, Y ;

Edmunds, JJ ;

Winocour, PD ;

Leblond, L ;

Siddiqui, MA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (03) :287-290

[10]

BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395

← 1 2 3 4 5 6 7 8 9 10 →